
Ep192: Kate Haviland on Following the Science to Precision Immunology
08/01/2026
0:00
1:26:06
Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.
D'autres épisodes de "The Long Run with Luke Timmerman"



Ne ratez aucun épisode de “The Long Run with Luke Timmerman” et abonnez-vous gratuitement à ce podcast dans l'application GetPodcast.







